About NVCT

Founded: 2020
Employees: 12
CEO: Ron Bentsur
WebsiteView website: www.nuvectis.com

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Recent NVCT News & Updates

New Risk • May 05

New minor risk - Shareholder dilution

The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$27m net loss in 3 years). Shareholders have been diluted in the past year (18% increase in shares outstanding).

Recent updates

No updates

Nuvectis Pharma, Inc. Stock Price

NVCT Share Price Performance

NVCT Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Nuvectis Pharma, Inc. Key Details

About NVCT

Recent NVCT News & Updates

Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth

New minor risk - Shareholder dilution

Nuvectis Pharma, Inc., Annual General Meeting, Jun 11, 2026

Recent updates

Nuvectis Pharma, Inc. Competitors

Jade Biosciences

BioAge Labs

Xencor

MeiraGTx Holdings